Schrock et al. identified KRAS, TP53, and APC mutations in duodenal adenocarcinoma, along with higher CDKN2A/B and ERBB2/HER2 mutational frequencies compared to other small intestinal malignancies [33], whereas Yuan et al. revealed the critical role of the WNT/β-catenin pathway in duodenal adenocarcinoma progression through whole-exome sequencing [34]. This evidence concerns the gene TP53 and duodenal adenocarcinoma.